Disc Medicine's strong financial position ensures funding through 2028, ... Disc Medicine: Forging Ahead In Hematology. Apr. 09, 2025 7:13 AM ET Disc Medicine, Inc. (IRON) ...

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 PRESS RELEASE GlobeNewswire Jan. 10, 2025, 09:00 AM ...

Disc Medicine to present hematology data at EHA 2025, including findings on bitopertin and DISC-0974 for blood disorders. Quiver AI Summary. Disc Medicine, Inc. announced it will present data from ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and ...

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress Provided by GlobeNewswire May 14, 2025, 1:30:00 PM ...

Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional ...

--Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic ...

Additional data from the ongoing Phase 1b trial of DISC-0974 in myelofibrosis (MF) patients continued to demonstrate greater than 60% hematologic response rates, with durable increases in ...

CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for ...

CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for ...